Merck (MRK) Net Income towards Common Stockholders (2009 - 2026)
Merck (MRK) reported Net Income towards Common Stockholders of -$4.2 billion for Q1 2026, down 182.77% year-over-year from $5.1 billion in Q1 2025, and down 242.1% on a QoQ basis from $3.0 billion in Q4 2025.
Merck (MRK) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$4.2 billion in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 182.77% year-over-year to -$4.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 billion (down 48.61% YoY) and the FY2025 annual result came in at $18.3 billion, up 6.6% from the prior year.
- Net Income towards Common Stockholders eased to -$4.2 billion in Q1 2026 per MRK's latest filing, from $3.0 billion in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.8 billion in Q3 2025 and bottomed at -$5.9 billion in Q2 2023.
- The 4-year median for Net Income towards Common Stockholders is $3.7 billion (2024), against an average of $2.4 billion.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders jumped 405.38%; it then plunged 182.77% in 2026.
- Tracing MRK's Net Income towards Common Stockholders over 4 years: stood at -$1.2 billion in 2023, then jumped by 405.38% to $3.7 billion in 2024, then fell by 20.89% to $3.0 billion in 2025, then slumped by 242.1% to -$4.2 billion in 2026.
- Per Business Quant, the three latest MRK Net Income towards Common Stockholders figures stand at -$4.2 billion (Q1 2026), $3.0 billion (Q4 2025), and $5.8 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.40 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 5.24 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 697.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -4.21 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.82 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 2.02 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -13.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 2.68 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.21 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.94 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2021 | -62.00 Mn |
| Jun 30, 2021 | 332.00 Mn |
| Mar 31, 2021 | 437.00 Mn |
| Dec 31, 2020 | 523.00 Mn |
| Sep 30, 2020 | 617.00 Mn |
| Jun 30, 2020 | 661.00 Mn |
| Mar 31, 2020 | 3.22 Bn |
| Dec 31, 2019 | -1.81 Bn |
| Sep 30, 2019 | 1.91 Bn |
| Jun 30, 2019 | 2.64 Bn |
| Mar 31, 2019 | 2.86 Bn |
| Dec 31, 2018 | 1.78 Bn |
| Sep 30, 2018 | 1.96 Bn |
| Jun 30, 2018 | 1.72 Bn |
| Mar 31, 2018 | 741.00 Mn |
| Dec 31, 2017 | -1.04 Bn |
| Sep 30, 2017 | -51.00 Mn |
| Jun 30, 2017 | 1.95 Bn |
| Mar 31, 2017 | 1.56 Bn |
| Dec 31, 2016 | -587.00 Mn |
| Sep 30, 2016 | 2.19 Bn |
| Jun 30, 2016 | 1.21 Bn |
| Mar 31, 2016 | 1.13 Bn |
| Dec 31, 2015 | 982.00 Mn |
| Sep 30, 2015 | 1.83 Bn |
| Jun 30, 2015 | 688.00 Mn |
| Mar 31, 2015 | 958.00 Mn |
| Dec 31, 2014 | 7.33 Bn |
| Sep 30, 2014 | 842.00 Mn |
| Jun 30, 2014 | 2.03 Bn |
| Mar 31, 2014 | 1.73 Bn |
| Dec 31, 2013 | 815.00 Mn |
| Sep 30, 2013 | 1.15 Bn |
| Jun 30, 2013 | 935.00 Mn |
| Mar 31, 2013 | 1.62 Bn |
| Dec 31, 2012 | -1.49 Bn |
| Sep 30, 2012 | 1.76 Bn |
| Jun 30, 2012 | 1.82 Bn |
| Mar 31, 2012 | 1.77 Bn |
| Dec 31, 2011 | -883.00 Mn |
| Sep 30, 2011 | 1.72 Bn |
| Jun 30, 2011 | 2.05 Bn |
| Mar 31, 2011 | -1.38 Bn |
| Dec 31, 2010 | -4.08 Bn |
| Sep 30, 2010 | -2.08 Bn |
| Jun 30, 2010 | -1.65 Bn |
| Mar 31, 2010 | -2.11 Bn |
| Dec 31, 2009 | 11.02 Bn |
| Sep 30, 2009 | 477.00 Mn |
| Jun 30, 2009 | 633.00 Mn |
| Mar 31, 2009 | 802.80 Mn |